Intrasurgical Optical Coherence Tomography

Information

  • Research Project
  • 9006007
  • ApplicationId
    9006007
  • Core Project Number
    R44EY024846
  • Full Project Number
    4R44EY024846-02
  • Serial Number
    024846
  • FOA Number
    PA-13-234
  • Sub Project Id
  • Project Start Date
    9/30/2014 - 10 years ago
  • Project End Date
    2/28/2017 - 7 years ago
  • Program Officer Name
    WUJEK, JEROME R
  • Budget Start Date
    3/1/2015 - 9 years ago
  • Budget End Date
    2/29/2016 - 8 years ago
  • Fiscal Year
    2015
  • Support Year
    02
  • Suffix
  • Award Notice Date
    2/27/2015 - 9 years ago
Organizations

Intrasurgical Optical Coherence Tomography

DESCRIPTION (provided by applicant): Each year, over 20 million ophthalmic surgeries are performed worldwide. Indications for ophthalmic surgery include potentially blinding diseases, such as cataracts, diabetic retinopathy, macular disease, and retinal detachment. Surgeons performing these delicate procedures are challenged by the translucent nature of tissues in the eye, making it nearly impossible to visualize microstructural changes during surgery. Optical coherence tomography (OCT) is a non-contact, optical imaging modality that provides high-resolution cross-sectional images of the various layers of the anterior and posterior eye. OCT is also commonly used to aid in ophthalmic surgical planning and post-operative assessment, and more recently, has been used perioperatively. Intraoperative OCT offers the surgeon the ability to see the microstructure of the eye in a way not possible with conventional surgical microscopes. By improving tissue visualization and providing surgical feedback, intraoperative OCT will enhance surgical precision, decrease surgical trauma, aid in surgical decision-making and ultimately improve functional and anatomical outcomes. Bioptigen is at the forefront of intrasurgical OCT imaging technology, with the only OCT system on the market with an FDA approved indication for intrasurgical imaging. Currently, intrasurgical imaging is performed using a hand-held probe, or by mounting such a probe to the surgical microscope. In this proposal, we describe the development of an intraoperative OCT system integrated directly into the optical train of the surgical microscope. In Phase I, we will complete development of the SMI and integrate it with our OCT engine technology. We will also verify the optical performance of the SMI. In Phase II, Bioptigen will focus on the development of surgery-specific software. Initial testing and evaluation of the intraoperative OCT system will also be performed in Phase II, in collaboration with the Cole Eye Institute at the Cleveland Clinic. This initial testing will includ laboratory feasibility testing, quality assessment, and ergonomic evaluation. Following initial testing, our collaborators will perform simulated surgical procedures with intraoperative OCT. Feedback from these initial tests and simulated surgeries will be used to iterate on system design in preparation for human clinical studies. Ultimately, the commercialization of intraoperative OCT technology will bring state-of-the-art OCT imaging technology to the surgical bedside, improving the quality of care for millions of patients each year.

IC Name
NATIONAL EYE INSTITUTE
  • Activity
    R44
  • Administering IC
    EY
  • Application Type
    4
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    955139
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    867
  • Ed Inst. Type
  • Funding ICs
    NEI:955139\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    BIOPTIGEN, INC.
  • Organization Department
  • Organization DUNS
    361420040
  • Organization City
    DURHAM
  • Organization State
    NC
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    277093569
  • Organization District
    UNITED STATES